188 related articles for article (PubMed ID: 16556667)
21. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours.
Fosså SD; Stenning SP; Gerl A; Horwich A; Clark PI; Wilkinson PM; Jones WG; Williams MV; Oliver RT; Newlands ES; Mead GM; Cullen MH; Kaye SB; Rustin GJ; Cook PA
Br J Cancer; 1999 Jul; 80(9):1392-9. PubMed ID: 10424741
[TBL] [Abstract][Full Text] [Related]
22. Carcinoid tumours of the testis.
Stroosma OB; Delaere KP
BJU Int; 2008 May; 101(9):1101-5. PubMed ID: 18190641
[TBL] [Abstract][Full Text] [Related]
23. Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome.
Haq M; Harmer C
Clin Endocrinol (Oxf); 2005 Jul; 63(1):87-93. PubMed ID: 15963067
[TBL] [Abstract][Full Text] [Related]
24. Principal component analysis, hierarchical clustering, and decision tree assessment of plasma mRNA and hormone levels as an early detection strategy for small intestinal neuroendocrine (carcinoid) tumors.
Modlin IM; Gustafsson BI; Drozdov I; Nadler B; Pfragner R; Kidd M
Ann Surg Oncol; 2009 Feb; 16(2):487-98. PubMed ID: 19050963
[TBL] [Abstract][Full Text] [Related]
25. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group.
di Bartolomeo M; Bajetta E; Buzzoni R; Mariani L; Carnaghi C; Somma L; Zilembo N; di Leo A
Cancer; 1996 Jan; 77(2):402-8. PubMed ID: 8625251
[TBL] [Abstract][Full Text] [Related]
26. Prediction of prognosis and surgical indications for pulmonary metastasectomy from colorectal cancer.
Iizasa T; Suzuki M; Yoshida S; Motohashi S; Yasufuku K; Iyoda A; Shibuya K; Hiroshima K; Nakatani Y; Fujisawa T
Ann Thorac Surg; 2006 Jul; 82(1):254-60. PubMed ID: 16798225
[TBL] [Abstract][Full Text] [Related]
27. Midgut carcinoid tumours: surgical treatment and prognosis.
Kerström G; Hellman P; Hessman O
Best Pract Res Clin Gastroenterol; 2005 Oct; 19(5):717-28. PubMed ID: 16253896
[TBL] [Abstract][Full Text] [Related]
28. Gastrointestinal carcinoids. Prognosis and survival.
Caprotti R; Angelini C; Mussi C; Romano F; Sartori P; Scaini A; Muselli P; Uggeri F
Minerva Chir; 2003 Aug; 58(4):523-28,529-32. PubMed ID: 14603164
[TBL] [Abstract][Full Text] [Related]
29. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients.
Safford SD; Coleman RE; Gockerman JP; Moore J; Feldman J; Onaitis MW; Tyler DS; Olson JA
Cancer; 2004 Nov; 101(9):1987-93. PubMed ID: 15455358
[TBL] [Abstract][Full Text] [Related]
30. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs.
Khuroo MS; Khuroo MS; Khuroo NS
J Gastroenterol Hepatol; 2010 Mar; 25(3):548-54. PubMed ID: 20074162
[TBL] [Abstract][Full Text] [Related]
31. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours.
Modlin IM; Pavel M; Kidd M; Gustafsson BI
Aliment Pharmacol Ther; 2010 Jan; 31(2):169-88. PubMed ID: 19845567
[TBL] [Abstract][Full Text] [Related]
32. Neurokinin A monitoring of response to interferon alpha in a patient with an advanced small bowel neuroendocrine tumour uncontrolled by somatostatin analogue therapy.
Ardill JE; Johnston BT; McCance DR; Eatock M
Ann Clin Biochem; 2017 Mar; 54(2):297-301. PubMed ID: 27638929
[TBL] [Abstract][Full Text] [Related]
33. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
Pentheroudakis G; Fountzilas G; Bafaloukos D; Koutsoukou V; Pectasides D; Skarlos D; Samantas E; Kalofonos HP; Gogas H; Pavlidis N
Breast Cancer Res Treat; 2006 Jun; 97(3):237-44. PubMed ID: 16322882
[TBL] [Abstract][Full Text] [Related]
34. Monitoring the treatment of carcinoid disease using blood serotonin and plasma 5-hydroxyindoleacetic acid: three case examples.
Allen KR; Degg TJ; Anthoney DA; Fitzroy-Smith D
Ann Clin Biochem; 2007 May; 44(Pt 3):300-7. PubMed ID: 17456301
[TBL] [Abstract][Full Text] [Related]
35. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours.
Welin SV; Janson ET; Sundin A; Stridsberg M; Lavenius E; Granberg D; Skogseid B; Oberg KE; Eriksson BK
Eur J Endocrinol; 2004 Jul; 151(1):107-12. PubMed ID: 15248829
[TBL] [Abstract][Full Text] [Related]
36. An evaluation of cyclooxygenase-2 as a prognostic biomarker in mid-gut carcinoid tumours.
Cadden I; Johnston BT; Turner G; McCance D; Ardill J; McGinty A
Neuroendocrinology; 2007; 86(2):104-11. PubMed ID: 17700013
[TBL] [Abstract][Full Text] [Related]
37. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer.
Bramwell VH; Doig GS; Tuck AB; Wilson SM; Tonkin KS; Tomiak A; Perera F; Vandenberg TA; Chambers AF
Breast Cancer Res Treat; 2009 Apr; 114(3):503-11. PubMed ID: 18437556
[TBL] [Abstract][Full Text] [Related]
38. Levels of angiogenic peptides in sera from patients with carcinoid tumours during alpha-interferon treatment.
Nilsson A; Janson ET; Eriksson B; Larsson A
Anticancer Res; 2001; 21(6A):4087-90. PubMed ID: 11911297
[TBL] [Abstract][Full Text] [Related]
39. Carcinoid tumors--somatostatine in the diagnosis and therapy.
Kinova S; Duris I; Kratochvilova E; Ondrejka P; Payer J
Bratisl Lek Listy; 2002; 103(3):108-12. PubMed ID: 12190042
[TBL] [Abstract][Full Text] [Related]
40. Neuroendocrine tumours of the small bowel: interpretation of raised circulating chromogranin A, urinary 5 hydroxy indole acetic acid and circulating neurokinin A.
Ardill JE; Armstrong L; Smye M; Doherty R; McCance DR; Johnston BT
QJM; 2016 Feb; 109(2):111-5. PubMed ID: 25979268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
